아페레시스 장비 시장 : 제품 유형, 기술 유형, 환자 유형, 용도, 최종 사용자, 유통 채널별 예측(2026-2032년)

The Apheresis Equipment Market is projected to grow by USD 6.45 billion at a CAGR of 9.33% by 2032.

Apheresis Equipment Market Introduction

Apheresis equipment is central to modern transfusion medicine, therapeutic apheresis, stem cell collection, and plasma-derived therapies. These systems separate whole blood into components such as plasma, platelets, red cells, leukocytes, or hematopoietic stem cells, enabling targeted collection or removal while returning remaining components to the donor or patient.

The market is supported by well-established clinical use cases, including plateletpheresis, plasmapheresis, leukapheresis, extracorporeal photopheresis support workflows, and therapeutic plasma exchange. Demand is reinforced by aging populations, cancer care expansion, autoimmune and hematologic disease management, trauma preparedness, and continued reliance on plasma fractionation for immunoglobulins, albumin, and coagulation factors.

Transformative Shifts in the Apheresis Landscape

The apheresis equipment landscape is shifting from manual, labor-intensive workflows toward automated, software-guided systems designed to improve collection efficiency, operator consistency, and patient safety. Modern platforms increasingly emphasize closed or functionally closed fluid pathways, integrated anticoagulant control, automated interface detection, configurable protocols, and real-time procedure monitoring.

A second transformation is the convergence of apheresis with cell and gene therapy supply chains. Leukapheresis and mononuclear cell collection are critical upstream steps for CAR-T and other advanced therapies, making collection quality, chain-of-identity controls, chain-of-custody documentation, and digital traceability strategic differentiators for hospitals, blood centers, and therapy developers.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence apheresis equipment through decision support rather than autonomous clinical replacement. AI-enabled analytics can support donor and patient scheduling, procedure parameter optimization, adverse event risk flagging, inventory planning, quality trend detection, and predictive maintenance for high-utilization blood center and hospital environments.

The cumulative impact depends on governance. AI applications connected to apheresis workflows must align with medical device quality systems, cybersecurity expectations, clinical validation, data privacy laws such as HIPAA and GDPR, and internationally recognized risk management practices such as ISO 14971. The strongest near-term value is expected in workflow efficiency, quality assurance, utilization management, and equipment uptime.

Key Regional Insights

Asia-Pacific is expanding through rising healthcare investment, large patient populations, increasing oncology care, and growing demand for plasma-derived medicinal products. China, India, Japan, South Korea, and Australia are important anchors, with Japan and Australia supported by mature transfusion systems and China and India advancing capacity across hospitals, blood services, and specialty centers.

North America remains a high-adoption region because of established blood collection infrastructure, FDA-regulated device pathways, strong therapeutic apheresis use, active cellular therapy programs, and extensive plasma collection activity. Latin America shows selective expansion led by Brazil and Mexico, where private hospital networks, public health investment, and tertiary care development support demand for donor and therapeutic apheresis. Europe benefits from structured hemovigilance, EU medical device regulation, mature transfusion networks, and advanced hospital systems, while the Middle East is investing in tertiary care capacity, oncology services, and national health infrastructure, particularly in GCC countries. Africa's opportunity is tied to blood safety modernization, donor infrastructure, infectious disease screening capacity, and improved access to specialty treatment in major urban medical centers.

Key Group Insights

ASEAN demand is shaped by hospital modernization, improving blood services, medical tourism, and expanding private healthcare networks in countries such as Singapore, Thailand, Malaysia, Indonesia, and Vietnam. The GCC is investing in specialty hospitals, oncology services, transplant programs, and national self-sufficiency goals, creating demand for reliable therapeutic apheresis and donor collection systems.

The European Union is defined by stringent quality, safety, and regulatory requirements, including medical device conformity, blood establishment standards, hemovigilance, and cross-border healthcare quality frameworks. BRICS countries represent scale-driven opportunity, especially where plasma demand, oncology care, and cell therapy programs are expanding alongside broader healthcare infrastructure. G7 markets lead in clinical adoption, reimbursement maturity, evidence-based protocols, and advanced therapy integration, while NATO countries emphasize resilient blood supply chains, emergency preparedness, interoperable healthcare logistics, and continuity of critical medical services.

Key Country Insights

The United States leads in plasma collection scale, therapeutic apheresis adoption, and advanced cellular therapy infrastructure, while Canada benefits from organized blood systems, strong hospital-based care, and established clinical governance. Mexico and Brazil are expanding access through public and private healthcare investment, with Brazil serving as a key Latin American healthcare hub for tertiary care, transfusion services, and specialty medicine.

The United Kingdom, Germany, France, Italy, and Spain maintain advanced transfusion and hospital networks supported by clinical standards, hemovigilance practices, and specialist treatment pathways, while Germany is especially notable for high medical technology adoption and robust hospital infrastructure. Russia has a broad hospital base but faces procurement, access, and supply chain constraints. China and India offer large-volume demand potential driven by population scale, oncology expansion, blood service development, and healthcare investment; Japan and South Korea provide technologically mature markets supported by high clinical standards and advanced hospital systems; and Australia combines strong transfusion governance, high clinical quality expectations, and regional reference capabilities across the Asia-Pacific healthcare ecosystem.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize platforms that reduce operator variability, improve collection yield, enhance patient and donor safety, and integrate seamlessly with blood bank information systems, hospital electronic records, laboratory systems, and cell therapy manufacturing workflows. Investments in closed-system design, consumable reliability, cybersecurity, remote diagnostics, and service responsiveness can strengthen competitive positioning.

Manufacturers and providers should also build evidence packages around procedure efficiency, adverse event reduction, product quality, staff workflow, training efficiency, and total cost of ownership. Partnerships with blood centers, oncology networks, transplant programs, and cell therapy developers can accelerate adoption, while regulatory-ready AI governance and validated digital traceability can create durable differentiation.

Research Methodology

The research approach combines secondary research from regulatory authorities, public health agencies, clinical guidelines, scientific literature, healthcare infrastructure data, and publicly available industry documentation. Sources typically include FDA device information, European regulatory frameworks, WHO blood safety resources, transfusion medicine guidance, clinical practice recommendations, and peer-reviewed publications.

Market interpretation is strengthened through triangulation across device adoption patterns, procedure volumes where publicly available, disease burden indicators, blood and plasma collection trends, hospital capacity, reimbursement context, regulatory requirements, and procurement behavior. Insights are validated by comparing regional dynamics, clinical use cases, technology readiness, and healthcare system maturity across established and emerging markets.

Conclusion

Apheresis equipment is moving from specialized transfusion infrastructure toward a strategic platform for precision medicine, plasma supply, therapeutic intervention, and advanced therapy manufacturing. Growth drivers are supported by clinical necessity, technology automation, digital traceability, and rising demand for safe, standardized blood component collection and therapeutic procedures.

The strongest market participants will combine clinical reliability, digital interoperability, regulatory discipline, service excellence, and evidence-based value demonstration. As AI, cell therapy, plasma-derived medicine demand, and regional healthcare investment reshape adoption priorities, apheresis equipment providers that deliver measurable workflow, safety, and quality improvements will be best positioned for long-term growth.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Apheresis Equipment Market, by Product Type

• 7.1. Disposable Apheresis Kits
  • 7.1.1. Blood Tubing Sets
  • 7.1.2. Filters
  • 7.1.3. Needles & Catheters
• 7.2. Apheresis Devices
  • 7.2.1. Automated Apheresis Machines
  • 7.2.2. Semi-Automated Apheresis Machines

8. Apheresis Equipment Market, by Technology Type

• 8.1. Centrifugation Technology
• 8.2. Membrane Filtration Technology
  • 8.2.1. Hollow Fiber Filtration
  • 8.2.2. Selective Plasma Filtration
• 8.3. Adsorption Technology
• 8.4. Photopheresis Technology

9. Apheresis Equipment Market, by Patient Type

• 9.1. Adult
• 9.2. Pediatric

10. Apheresis Equipment Market, by Application

• 10.1. Blood Collection
  • 10.1.1. Plasma Collection
  • 10.1.2. Platelet Collection
  • 10.1.3. RBC Collection
  • 10.1.4. Stem Cell Collection
• 10.2. Therapeutic
  • 10.2.1. Neurological Disorders
    • 10.2.1.1. Guillain-Barre Syndrome
    • 10.2.1.2. Myasthenia Gravis
    • 10.2.1.3. Multiple Sclerosis
  • 10.2.2. Hematological Disorders
    • 10.2.2.1. Leukemia
    • 10.2.2.2. Sickle Cell Disease
    • 10.2.2.3. Thrombocytopenia
  • 10.2.3. Renal Diseases
    • 10.2.3.1. Kidney Failure
    • 10.2.3.2. Glomerulonephritis
  • 10.2.4. Autoimmune Diseases

11. Apheresis Equipment Market, by End User

• 11.1. Blood Banks
• 11.2. Specialty Clinics
• 11.3. Hospitals
  • 11.3.1. Public Hospitals
  • 11.3.2. Private Hospitals
• 11.4. Research Institutes

12. Apheresis Equipment Market, by Distribution Channel

• 12.1. Online
• 12.2. Offline

13. Apheresis Equipment Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Apheresis Equipment Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Apheresis Equipment Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Aferetica srl
• 17.2. Asahi Kasei Medical Co., Ltd.
• 17.3. B. Braun SE
• 17.4. Baxter International Inc.
• 17.5. Beijing ZKSK Technology Co., Ltd.
• 17.6. Bioelettronica S.r.l.
• 17.7. Cerus Corporation
• 17.8. Cytosorbents Corporation
• 17.9. Fresenius SE & Co. KGaA
• 17.10. Guangzhou Daji Medical Science and Technology Co., Ltd.
• 17.11. Haemonetics Corporation
• 17.12. Haier Biomedical
• 17.13. Infomed SA
• 17.14. Jafron Biomedical Co., Ltd.
• 17.15. Kaneka Corporation
• 17.16. Kawasumi Laboratories, Inc.
• 17.17. Macopharma SA
• 17.18. Medica S.p.A.
• 17.19. Miltenyi Biotec B.V. & Co. KG
• 17.20. Nikkiso Co., Ltd.
• 17.21. PuriBlood Medical Co., Ltd.
• 17.22. Terumo BCT, Inc.
• 17.23. Therakos, Inc.